Biomind Labs to Participate in the PSYCH Symposium at the National Gallery in London

Rhea-AI Summary

Biomind Labs Inc. (OTC: BMNDF) announced its participation in the PSYCH Symposium on May 11, 2022, at The National Gallery in London. CEO Alejandro Antalich emphasized the event's significance in the psychedelic industry, aiming to foster discussions on mental health treatment advancements. The UK is becoming a leader in psychedelic research, advocating for greater collaboration and regulatory analysis. Biomind Labs focuses on developing novel pharmaceutical formulations of psychedelic compounds to address psychiatric and neurological disorders, promoting accessible treatments for patients.

TORONTO--(BUSINESS WIRE)-- Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce that it will be participating in the “PSYCH Symposium: London 2022 – Unlocking the potential of psychedelic Healthcare” to be held at The National Gallery on Wednesday, May 11, 2022.

Alejandro Antalich, CEO of Biomind Labs commented: “The PSYCH Symposium will be one of the most relevant events in the psychedelic industry in 2022, and this is the reason why we have decided to be part of the debates with the principal leaders of the sector and use this forum to present our future plans.

Last year Prime Minister Boris Johnson said that he will examine the latest advice on the legalization of a psychedelic drug. We must confess that with this statement, Prime Minister Johnson won our respect because as a leader of a nation, he displayed empathy towards millions of patients that suffer from any kind of mental health disorder, and this kind of attitude is what is needed from global leaders.

We support the initiative of Mr. Crispin Blunt that has had a positive impact on Primer Minister Johnson, with the hope of promoting a global analysis and review of psychedelic legalization by government authorities, regulators and the psychiatry community. While more clinical research must be done, time is becoming critical for the almost one billion people that are affected by mental disorders”, concluded Mr. Antalich.

The United Kingdom is home to world-leading psychedelic research institutions, which lays the foundation for a flourishing domestic industry, with the PSYCH Symposium championing the emerging ecosystem. The PSYCH Symposium is a unique experience that enables industry leaders to collaborate to expedite access to psychedelic healthcare across Europe. As the industry expands, research briefings, regulatory updates and topical debates can provide the intelligence and insights to navigate this burgeoning landscape, while ensuring a sustainable, patient-first approach to how the industry defines itself in the future.

About Biomind Labs Inc.

Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine, 5-MeO- DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always

using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this document include, among others, statements relating to the Company’s ability to scientifically harness the medicinal power of psychedelic molecules to treat patients suffering from neurological and psychiatric disorders, the possibility of a global analysis and review of psychedelic legalization by government authorities, regulators and the psychiatry community, any statement regarding the future impact of the PSYCH Symposium, the business plans and growth plans of the Company, the burgeoning landscape of the psychedelic industry, and other statements that are not historical facts.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company’s business and results of operations; (d) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company’s securities, regardless of its operating peers; (e) adverse changes in the public perception of tryptamine- based treatments and psychedelic-based therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments, psychedelic-based therapies or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not yet completed commercial clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in commercial clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The Neo Exchange Inc. has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005644/en/

Biomind Labs Inc.

Alejandro Antalich

Chief Executive Officer

Email: info@biomindlabs.com

Tel: + 598 97 702500

Source: Biomind Labs Inc.

FAQ

What is Biomind Labs' participation in the PSYCH Symposium on May 11, 2022?

Biomind Labs Inc. will participate in the PSYCH Symposium in London to discuss advancements in psychedelic healthcare.

What are Biomind Labs' plans for psychedelic treatments?

Biomind Labs focuses on developing pharmaceutical formulations using psychedelic compounds to treat psychiatric and neurological disorders.

How is the UK supporting psychedelic research?

The UK is home to leading psychedelic research institutions, promoting a flourishing industry and encouraging collaboration through events like the PSYCH Symposium.

What is the significance of the PSYCH Symposium for the psychedelic industry?

The PSYCH Symposium serves as a platform for industry leaders to discuss regulatory updates and strategies to improve access to psychedelic healthcare.

What challenges does Biomind Labs face in developing psychedelic treatments?

Biomind Labs faces challenges such as regulatory compliance, market volatility, and the need for further clinical research in psychedelic treatments.